SCFA supplements during belly/pelvis radiation for cancer
Part of Cancer, Digestive system, Injuries & trauma clinical trials.
This early-phase study tests whether an SCFA (fatty-acid) supplement can improve how patients tolerate radiation to the abdomen or pelvis. Participants are randomly assigned to receive the supplement or a comparison treatment, while they receive their planned radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old and sign consent (including permission to access medical records).
- Have a confirmed GI, urinary, or gynecologic cancer that is being treated with belly/pelvis radiation (at least 40 Gy).
- Be well enough for study participation (doctor says you’re healthy; performance score 0 to 2).
- Have finished any chemotherapy or surgery at least 14 days ago and be back near your usual baseline for side effects.
- If you can become pregnant: have a negative pregnancy test and agree to two reliable birth-control methods during treatment and for a short time after.
- Be able to follow all study steps, including blood draws and other visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of a special diet supplement (beta-hydroxybutyrate), short radiation therapy, immunotherapy, and chemotherapy before surgery for locally advanced rectal cancer. The goal is to see if this approach helps shrink the tumor and improve treatment outcomes.
This trial tests an oral probiotic (a mix of 5 good bacteria) to see if it can reduce stomach and bowel side effects from pelvic radiation. It may help people undergoing radiation for certain pelvic cancers.
This study tests a new type of very-short-course radiation therapy combined with systemic treatment (medication) for older or frail people with colorectal cancer that cannot be removed by surgery. The goal is to see if this approach works well with fewer side effects.
This trial tests a shorter course of radiation to the pelvis to treat rectal cancer, with the goal of avoiding surgery and preserving the rectum. It may be an option for people with advanced rectal cancer that has not spread to other organs.
This trial tests if giving a short course of radiation before surgery, along with standard chemotherapy, can help treat stomach cancer. It is for people newly diagnosed with stomach cancer who have not had treatment before.
This Phase 1 study tests an “adaptive” form of focused radiation (SBRT) for cancers that have spread in the abdomen or pelvis. It aims to treat metastatic tumor spots safely while adjusting the plan as needed during treatment.
Hear when a new Toxicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.